BMRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BMRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biomarin Pharmaceutical's Enterprise Value for the quarter that ended in Jun. 2024 was $15,547 Mil. Biomarin Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $315 Mil. Biomarin Pharmaceutical's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2024 was 2.03%.
The historical rank and industry rank for Biomarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Biomarin Pharmaceutical was 2.44%. The lowest was -5.49%. And the median was -0.36%.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Biomarin Pharmaceutical's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
The historical data trend for Biomarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Earnings Yield (Joel Greenblatt) % | Get a 7-Day Free Trial | -0.48 | -0.13 | -0.37 | 0.86 | 1.13 |
Biomarin Pharmaceutical Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Earnings Yield (Joel Greenblatt) % | Get a 7-Day Free Trial | 0.76 | 1.00 | 1.13 | 1.53 | 2.03 |
For the Biotechnology subindustry, Biomarin Pharmaceutical's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Biomarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Biomarin Pharmaceuticals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings Yield (Joel Greenblatt) | = | EBIT | / | Enterprise Value |
= | 205.304 | / | 18206.56016 | |
= | 1.13 % |
Biomarin Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $315 Mil.
Biomarin Pharmaceutical (NAS:BMRN) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Erin Burkhart | officer: GVP, Chief Accounting Officer | C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901 |
Brian Mueller | officer: EVP, Chief Financial Officer | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
George Eric Davis | officer: VP, General Counsel | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Jean Jacques Bienaime | director, officer: Chief Executive Officer | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Jeffrey Robert Ajer | officer: EVP, Chief Commercial Officer | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Henry J Fuchs | officer: Chief Medical Officer | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Charles Greg Guyer | officer: EVP, Chief Technical Officer | C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901 |
Mark J Alles | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Elizabeth M Anderson | director | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Maykin Ho | director | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
V Bryan Lawlis | director | |
Richard A Meier | director | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
Dennis Slamon | director | 770 LINDARO STREET, SAN RAFAEL CA 94901 |
Michael G Grey | director | C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Pyott David E I | director | C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612 |
From GuruFocus
By PRNewswire • 05-04-2024
By GuruFocus Research • 04-25-2024
By GuruFocus Research • 02-27-2024
By PRNewswire • 09-04-2024
By GuruFocus Research • 03-08-2024
By GuruFocus Research • 08-05-2024
By PRNewswire • 08-21-2024
By PRNewswire • 03-01-2024
By GuruFocus Research • 08-06-2024
By GuruFocus Research • 04-01-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.